In preclinical studies, rapamycin-mediated activation of the translation inhibitor 4E-BP abolished degeneration of dopaminergic neurons and ameliorated mitochondrial defects in cells derived from PRKN-mutant PD patients [241]. Here, PRKN is linked to Parkinson disease.